Embryo transfer is one of the most sensitive and critical procedures in IVF
treatment. At Embryoland we use EmbryoGlue® for all embryo transfers. EmbryoGlue® is a
medium developed exclusively for embryo transfer and the only existing product
with a proven implantation-enhancing effect.
What is EmbryoGlue®?
EmbryoGlue® is a
product developed to closely resemble the environment in the uterus at the time
of implantation. It is not a glue in the common sense, but acts as a glue by
increasing the chance of implantation of the embryo to the uterus. EmbryoGlue®
is enriched with the carbohydrates and amino acids needed to support the embryo
during transfer and implantation. It has a relatively high concentration of
hyaluronan and also contains the safest protein source available, i.e.
Hyaluronan is a
natural substance abundant in all tissues in the body, and the levels of
hyaluronan increase in the uterus at the time of implantation. The uterine wall
and the embryo have receptor sites for this molecule. It is thought that the
hyaluronan in EmbryoGlue® acts like a bridge between the embryo and the uterus,
having a glue-like effect. Also, the higher concentration of hyaluronan
thickens the solution to be more similar to the consistency of the fluids in
the uterus. This allows better mixing of the medium and uterine fluids and is
believed to minimize drifting of the embryo.
Who should use EmbryoGlue®?
All patients going
through IVF procedures that result in a transfer can benefit from EmbryoGlue®.
A literature study by the independent research institute “Cochrane
Collaboration” covering all published results on the effects of increased
hyaluronan during embryo transfer shows an increase in implantation rate
compared to embryo transfer without hyaluronan. EmbryoGlue® is the only product
available that is enriched with hyaluronan. Other studies have demonstrated a
significant increase in the number of babies brought home for couples with a
wide range of infertility diagnoses. EmbryoGlue® has been shown to be
especially beneficial for patients above the age of 35, patients with
previously failed implantation, and patients with unexplained infertility.